Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Incyte Corporation is conducting a Phase 3b clinical ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 1 clinical trial titled ‘A PHASE 1, ...

Identifying specific biomarkers and clinical characteristics is crucial for predicting a patient's response to both existing and emerging treatments for chronic spontaneous urticaria, thereby moving ...

Integrative approaches targeting neurological and immune pathways may help break the itch–scratch cycle in atopic dermatitis, improving pruritus, stress, sleep, and patient outcomes.

Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced that it has entered into an exclusive strategic partnership with ...

Individuals presenting with one of several immune-mediated skin diseases may also have a substantially higher risk for keratoconus (KC), according to a large multicenter investigation published in ...

Apogee Therapeutics recently reported positive 16-week results from its APEX Phase 2 Part A trial, with APG777 meeting all primary and key secondary endpoints in moderate-to-severe atopic dermatitis ...

The vitiligo treatment landscape is evolving with a shift towards targeted therapies, which have shown encouraging results in promoting repigmentatio ...

Four out of 10 eczema patients struggle with sleep, and they may not volunteer that information unless you ask.

For patients with skin of color and atopic dermatitis (AD), lebrikizumab is efficacious and safe, according to a study ...

特应性皮炎（Atopic Dermatitis, AD）是一种令人困扰的慢性皮肤病，很多人可能会问：它究竟是什么病？为何有些人在公共场合也无法控制瘙痒？面对中重度特应性皮炎的患者，他们的生活又是怎样的？ 特应性皮炎的病因复杂，主要与皮肤屏障功能受损、免疫系统失调以及神经系统相互作用有关。根据复旦大学附属华山医院的顾超颖教授，特应性皮炎是一种复发性炎症性疾病，全球有超过2.3亿人受到其影响。在中国， ...

A Japanese research team has found that cells often labeled “villains” for their roles in atopic dermatitis and asthma can ...